Study Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu.Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu.Trial opened at the following institutions: Medical University of South Carolina